deltatrials
Completed PHASE2 NCT00059475

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Randomized Comparison of Peptide Immunization in Patients at High Risk for Recurrence of Melanoma

Sponsor: National Cancer Institute (NCI)

Conditions Melanoma
Interventions 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1 Glycoprotein 100 (GP100): 209-217 (210M) Interleukin-2 (IL-2) Melanoma antigen recognized by T-cells (MART)-1: 27-35 Montanide ISA 51 melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
Updated 8 times since 2017 Last updated: Oct 17, 2012 Started: Apr 30, 2003 Primary completion: May 31, 2010 Completion: May 31, 2010

This PHASE2 trial investigates Melanoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States